Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Thiogenesis Therapeutics Corp has secured a key European patent for its innovative thiol compounds, enhancing its global intellectual property portfolio. The patent supports the company’s lead compound, TTI-0102, which aims to combat oxidative stress, a factor in chronic diseases like mitochondrial disorders and diabetes.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.